Maves review

What it is

Maves is a performance-framed telehealth brand whose treatment menu is organised by goal: sermorelin under muscle recovery, NAD+ under longevity, enclomiphene under testosterone, and compounded semaglutide and tirzepatide under weight loss. It presents itself around fat loss, lean muscle and energy rather than clinical weight management alone, and it also runs a set of free calculators as a content layer. It states that licensed providers prescribe personalised treatments, that it serves patients in all 50 US states through a nationwide network of licensed providers, and that no insurance is required.

How it works

Asynchronous and storefront-led. Each product card carries a starting price and a start button, so you can read the whole menu before entering an intake — which is the point of the design and the main reason to consider Maves. Its FAQ is explicit that plans include the medical consultation, prescription medications when approved by a licensed provider, ongoing clinical support and free shipping, with no hidden or additional fees, and free expedited shipping is stated across plans. The certification layer is real: LegitScript with a displayed seal ID that can be checked directly, and the FDA compounded-medication disclaimer printed in the brand's own words. The gaps are all on the supply and accountability side. The compounding pharmacy is described only as licensed US pharmacies and never named, the 503A or 503B pathway is not designated, no medical director or named clinical leadership appears anywhere, and no corporate address, refund policy or arbitration venue is published. Note also that the parent brand's own domain now resolves to an essentially blank page, so the consumer site is the only live destination.

Pricing transparency

Published, standalone and all-in. Sermorelin starts at $120/month and NAD+ starts at $149/month, both on the homepage product cards, with the consultation, medication, clinical support and shipping stated as included. That combination — a per-molecule figure, sold on its own rather than as an add-on, with the extras folded in — is unusual on this board and makes Maves directly comparable to competitors in a way that gated platforms are not. Two things to check. "Starting at" is doing work in both figures, so ask whether the price moves once a provider sets your dose, and ask what a month actually contains, since neither card publishes a dose or vial size. Separately, the GLP-1 line advertises a first-month intro rate that steps up afterwards; that is a weight-loss promotion and has nothing to do with the peptide pricing, so do not read the two together.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Maves states verbatim that compounded medications are not reviewed or approved by the FDA for safety or effectiveness, that a prescription is required and that individual results may vary — the correct disclosure — but it does not name the pharmacy, does not designate the compounding pathway, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the three molecules differ sharply. Sermorelin is a growth-hormone-releasing hormone analogue that prompts your own pituitary to release growth hormone, preserving the feedback loop that injected HGH overrides; the mechanism is real and well characterised, and the long-term human outcome data behind the recovery, body-composition and energy claims stays thin. Injected NAD⁺ has no controlled human outcome trials; the oral precursors NR and NMN are the studied forms and what they demonstrate is a raised blood NAD⁺ level rather than a clinical benefit. Enclomiphene raises endogenous testosterone by blocking oestrogen feedback at the pituitary and preserves fertility, but it is not FDA-approved for that use and is prescribed compounded. Individual results vary.

Pros and watch-outs

The evidence behind what Maves prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• Enclomiphene: the evidence for restoring testosterone without replacing it

  Randomized trials, including two Phase III RCTs, show enclomiphene restores a man's own testosterone while preserving fertility — but it was never FDA-approved.

How Maves compares

A few alternatives worth a look, depending on what you’re optimizing for.

• MEMeto

  NAD⁺ buyers who want bloodwork behind the prescription and the price published in advance

  See Meto →
• LULumora

  A certified 50-state NAD⁺ program if you will complete an assessment before seeing anything

  See Lumora →
• KOKongo

  NAD⁺ injections at a published flat rate across all 50 states

  See Kongo →